Pangaea Data partners with AstraZeneca to advance precision healthcare

Pangaea Data (Pangaea) is forming a multi-year strategic collaboration with AstraZeneca, to make AI-driven clinical decision-making available at scale, and improve how patients are identified, diagnosed, treated, and connected to existing therapies and clinical trials.

As part of the collaboration, AstraZeneca will sponsor the configuration, validation, and deployment of Pangaea’s out-of-the-box enterprise grade platform that fuses large scale clinical, imaging, genomic, pathology, and real-world data using the latest breakthroughs in generative and predictive AI from Microsoft.

“We are excited to collaborate with AstraZeneca on this mission to transform care by ensuring that patients are connected to life changing therapies and trials effectively in a compliant and financially sustainable manner,” said Vibhor?Gupta, PhD, founder and CEO, Pangaea?Data.

Pangaea already brings deep experience in deploying AI and advanced patient-intelligence platforms worldwide. Its clinical grade systems, which follow clinical guidelines and are validated by clinicians, are being used to close care gaps and optimize patient outcomes across multiple chronic conditions, oncology and rare diseases, according to the company. This includes Chronic Kidney Disease (CKD), Chronic Obstructive Pulmonary Disease (COPD), asthma, metastatic breast cancer, and gastric cancer.

This experience and expertise, coupled with the reach and impact of AstraZeneca will enable:

• Multimodal Models and Applications: AstraZeneca and Pangaea’s research teams will train and validate their existing multimodal models to further support clinical trials and point of care decisions.
• Patient-Intelligence Layer: Pangaea’s platform will apply its clinical-grade AI to discover untreated, misdiagnosed, and under-treated patients at scale, and generate cohorts and insights to inform physicians for patient management. These platform capabilities and their reach will then be further strengthened by its participation in both the NVIDIA Inception and Microsoft Pegasus programs.
• Ambient Listening and Agentic AI Orchestration: the early collaboration with Microsoft includes plans to connect Pangaea’s systems into existing clinical workflows where it will use ambient listening and agentic AI orchestration to enable real-time, context-aware recommendations at the point of care.
• Compute and Infrastructure: Microsoft Azure’s high-performance AI supercomputing clusters, powered by NVIDIA’s GPUs and Azure OpenAI Service, will provide the processing capacity to train, deploy and refine multimodal models quickly and securely.
• Data Fabric and Security: Microsoft Fabric and Azure confidential computing will then provide the secure, compliant, privacy-preserving foundation for global data collaboration.

Pangaea’s platform will support the discovery of eligible patients in real time for precision therapies and clinical trials based on guidelines and respective protocols. The platform’s AI will identify and highlight evidence-based treatment (or trial) recommendations and real-time insights within electronic health record (EHR) systems and workflows thereby helping clinicians to improve outcomes in a sustainable manner.

Through federated learning, differential privacy, and model monitoring, the collaboration allows Pangaea and AstraZeneca to scale innovation responsibly, putting patients first while protecting patient information and delivering care against global regulatory standards.

“This first wave marks a defining moment for precision healthcare and medicines development. By combining our scientific leadership with NVIDIA and Microsoft’s AI capabilities, and enabling real world reach through Pangaea Data, we believe this technology will support our aim to transform outcomes for millions of patients,” said David Dellamonica, global head of digital care pathway optimization, AstraZeneca.

For more information about this news, visit www.pangaeadata.ai.